Tag: Braf/Mek inhibitor

Attending the Society for Melanoma Research (SMR) Congress in the Big Easy allowed me to see how science continues to advance the treatment of #melanoma. The session “What does neoadjuvant efficacy tell us about immunotherapy versus targeted efficacy across disease stages?” Presented by Dr Keith Flaherty, M.D, Mass General Research Institute reviewed the data from…